



Russian International Kidney Cancer Symposium

*5-6 March 2015, Moscow
Intercontinental Hotel*

Organizers:

Russian Society of Clinical Oncology (Moscow)
Kidney Cancer Association (Chicago)

AGENDA

5 March 2015

09:00-09:15 Opening ceremony

Welcoming address from KCA (15 min) C. Konosky, Vice-President of KCA

Welcoming address from RUSSCO (10 min) S.A. Tjulandin, Chairman of RUSSCO

09:15-09:35 Epidemiology of renal cell carcinoma. What is the reason of increased morbidity?

– Current trends in Russia

P.S. Borisov, St. Petersburg City Oncology Dispensary (St. Petersburg)

09:35-10:10 Biology of RCC:

– Morphological heterogeneity

I.N. Sokolova, N.N. Blokhin Russian Cancer Research Center (Moscow)

– Molecular heterogeneity and clonal evolution

D.S. Mikhaylenko, Herzen Moscow Cancer Research Institute of the Russian Ministry of Health (Moscow)

Discussion (10 min)

10:20-10:40 Coffee break

10:40-11:10 Robotic-assisted partial nephrectomy is a new standard for surgical treatment of small tumors:

– Yes (15 min) – *Prof. G. Bratslavsky, SUNY Upstate Medical University (USA)*

– No (15 min) – *TBD*

Discussion (5 min)

11:15-11:55 A patient with 2 cm peripheral tumor in lower pole of the kidney:

– I would recommend partial nephrectomy (15 min)

B.Y. Alekseev, P.A. Herzen Moscow Cancer Research Institute of the Russian Ministry of Health (Moscow)

– I would recommend ablation of the tumor (15 min)

A.K. Nosov, N.N. Petrov Cancer Research Center (St. Petersburg)

– I would recommend active surveillance (10 min)

A.M. Popov, Medical Radiological Research Center (Obninsk)

Discussion (5 min)

12:00-12:25 Laparoscopic radical nephrectomy for locally advanced RCC

G. Bratslavsky, SUNY Upstate Medical University (USA)

Discussion (5 min)

13:00-14:00 Break

14:00-14:15 When biopsy of atypical metastases should be performed? (15 min)

R.V. Leonenkov, Saint Petersburg Cancer Center (Saint Petersburg)

14:15-14:30 Resection of single distant metastases (15 min)

A.K. Nosov, N.N. Petrov Cancer Research Center (St. Petersburg)

Discussion (10 min)

14:50-16:00 Invited abstracts

16:00-17:00 Dinner

6 March 2015

09:30-11:00 Who is your "ideal" patient for:

– Active surveillance (15 min)

B. Rini, Cleveland Clinic (USA)

– Systemic first-line therapy:

Who is your ideal sunitinib patient?

D.A. Nosov, N.N. Blokhin Russian Cancer Research Center (Moscow)

Who is your ideal bevacizumab patient?

B.Y. Alekseev, P.A. Herzen Moscow Cancer Research Institute (Moscow)

Who is your ideal pazopanib patient?

A.M. Popov, Medical Radiological Research Center (Obninsk)

Who is your ideal sorafenib patient?

V.B. Matveev, N.N. Blokhin Russian Cancer Research Center (Moscow)

Discussion (5 min)

11:00-11:20 Coffee-break

11:20-12:00 Debate: Sequential therapy for metastatic RCC

– Axitinib (15 min)

B. Rini, Cleveland Clinic (USA)

– Everolimus (15 min)

I. Tsimafeyeu, Kidney Cancer Research Bureau (Moscow)

Discussion (10 min)

12:00-13:00 Industry Symposia (1 hour)

13:10-13:50 Debate: Choice of the optimal regimen for targeted therapy:

– Standard (15 min)

L.Y. Vladimirova, Rostov Cancer Research Institute (Rostov-on-Don)

– Modified (intermittent, dose modification regimen etc.)

N.M. Volkov, S.M. Berezin Clinic (St. Petersburg)

Discussion (5 min)

13:50-14:40 Side effects:

– Side effects of VEGFR inhibitors

M.I. Volkova, N.N. Blokhin Russian Cancer Research Center (Moscow)

– Side effects of mTOR inhibitors

A.V. Snegovoy, N.N. Blokhin Russian Cancer Research Center (Moscow)

14:40-15:00 The future of targeted and immunotherapy in metastatic RCC

G.Y. Kharkevich, N.N. Blokhin Russian Cancer Research Center (Moscow)

Discussion (10 min)